Thursday , December 13 2018
Breaking News
Home / International Customs / Germany / Lower drug sales potential at Bayer underscores need for deals
Lower drug sales potential at Bayer underscores need for deals

Lower drug sales potential at Bayer underscores need for deals

FRANKFURT: Germany’s Bayer which acquired seed company Monsanto this year, reduced its combined sales estimate for its most promising experimental drugs, acknowledging it needs to do more to replenish the development pipeline.

At its capital markets day in London on Wednesday, it said the tally of peak sales potential of its five most promising drugs was more than 3.75 billion euros ($4.3 billion), compared with a target of more than 6 billion euros for the top six drugs reiterated as recently as June.

Bayer last week announced the sale of a number of businesses, around 12,000 job cuts and 3.3 billion euros in impairments.

Bayer faces a threat to revenues in 2024 when the patent on blockbuster heart drug Xarelto runs out. Sales from eye drug Eylea, its second-best selling drug, are expected to suffer from competing drugs before that.

Bayer said it halted trials testing its experimental uterine fibroids treatment vilaprisan, which it previously expected to generate peak annual sales of more than 1 billion euros, citing the risk of side effects.

It also no longer included a peak sales estimate for anetumab ravtansine, a drug for asbestos-linked cancer type mesothelioma, previously seen generating more than 2 billion euros in annual revenues.

The group’s former head of pharmaceuticals, Dieter Weinand, said a year ago there was still hope for anetumab despite a setback in a Phase II trial in 2017, but Weinand quit and was replaced by Sanofi (SASY.PA) executive Stefan Oelrich last month.